Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Two drugs. Two strategies. One industry in the middle of a rewiring.

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...